Download Files:
JH-RE-06
$350 – $965
Products Details
Product Description
– JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2].
Web ID
– HY-126214
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C20H16Cl3N3O4
References
– [1]Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11.|[2]REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9(8):OF17.
CAS Number
– 1361227-90-8
Molecular Weight
– 468.72
Compound Purity
– 99.81
SMILES
– O=C1C(C(CC(C)C)=O)=C(NC2=CC=C(Cl)C=C2Cl)NC3=C1C([N+]([O-])=O)=CC=C3Cl
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 5 mg/mL (ultrasonic)
Target
– DNA/RNA Synthesis
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
